A securities class action traces a seven-month sequence from Park Ha Biological Technology Co., Ltd.'s December 2024 public debut at $4.00 per share to its July 2025 surge above $41.49, followed by a 93% single-session collapse to $2.99 on July 8, 2025, which erased more than $1 billion in market value without any company announcement.